mRNA Purification Process
mRNA vaccine manufacturing — in vitro transcription, chromatography purification, dsRNA removal, and lipid nanoparticle formulation for COVID-19 and cancer immunotherapy
Process Overview
mRNA vaccines deliver genetic instructions for cells to produce antigen proteins, triggering immune responses. The manufacturing process synthesizes mRNA via in vitro transcription (IVT), purifies away reaction components and impurities (DNA template, dsRNA, abortive transcripts), and formulates into lipid nanoparticles (LNPs) for delivery. mRNA purity is critical—dsRNA contamination can cause innate immune activation and reduce vaccine efficacy.
Process Steps
1
Synthesis
In Vitro Transcription (IVT)
Combine DNA template (linearized plasmid or PCR product), ribonucleotide triphosphates (NTPs), T7 RNA polymerase, and buffer in a enzymatic reaction at 37°C for 2–4 hours. Add cap enzyme (Vaccinia capping enzyme) or use co-transcriptional capping with trinucleotide cap analogs (m7GpppG). Typical mRNA length: 1–5 kb for SARS-CoV-2 spike protein: ~3.8 kb.
Yield: 2–10 mg/mL
Key: NTP ratios, T7 quality
2
DNA Removal
DNase Treatment
Add DNase I to the IVT reaction to degrade the DNA template. Incubate at 37°C for 15–30 min. Stop reaction by adding EDTA. This removes the largest impurity (DNA template). Add cation exchange resin or perform phenol-chloroform extraction to remove digested DNA fragments and DNase.
Yield: >95%
DNA removal: >99%
3
Capture
Oligo dT Affinity Chromatography
Load the reaction mixture onto oligo dT cellulose or magnetic beads in low-salt buffer (20 mM Tris, pH 7.5). The poly(A) tail of mRNA hybridizes with oligo dT while NTPs, salts, proteins, and abortive transcripts flow through. Elute with hot water (65°C) or low salt buffer. This captures full-length mRNA and removes most impurities in one step.
Yield: 70–85%
Purity: 80–90%
4
dsRNA Removal
dsRNA Chromatography or Affinity Methods
Remove double-stranded RNA (dsRNA) by cellulose chromatography (dsRNA binds to cellulose via hydrophobic interactions) or affinity methods (anti-dsRNA antibodies coupled to beads). dsRNA is a potent immunostimulant and must be reduced to <0.1% of total RNA. Alternative: RNase III treatment followed by another purification step.
Yield: 60–80%
dsRNA: <0.1%
5
Buffer Exchange
Tangential Flow Filtration (TFF)
Diafilter into final buffer (citrate buffer, pH 3.5–4.0 for stability) using 100–300 kDa MWCO membranes. mRNA (~1–5 MDa depending on length) is retained while small impurities and salts pass through. Concentrate to final mRNA concentration (0.5–2 mg/mL). Filter through 0.22 μm for sterility before LNP formulation.
Yield: >90%
Conc: 0.5–2 mg/mL
6
Formulation
Lipid Nanoparticle (LNP) Encapsulation
Mix mRNA in aqueous phase with lipids (ionizable lipid, DSPC, cholesterol, PEG-lipid) in ethanol using microfluidic mixers or T-junction devices. The mRNA is encapsulated in LNPs (80–100 nm) during the mixing process. Dialyze or TFF to remove ethanol and exchange buffer. Final LNP product is sterile filtered and stored at −20°C or −70°C.
Encapsulation: >90%
Size: 80–100 nm
mRNA Quality Specifications
| Parameter | GMP Requirement | Method |
|---|
| Full-length mRNA | >90% | Capillary electrophoresis (CE) |
| dsRNA content | <0.1% | dsRNA ELISA or immunoblot |
| DNA template | <0.1 ng/μg | qPCR |
| Endotoxin | <10 EU/mL | LAL assay |
| 5′ Cap (Cap1) | >95% | LC-MS or RNase mapping |
| Poly(A) tail | >80% intact | Hybridization assay |
| LNP size | 80–100 nm | Dynamic light scattering (DLS) |
Cost Considerations
| Step | Key Cost Driver | Relative Cost |
|---|
| IVT | NTPs, enzymes, DNA template | Medium–High |
| DNase | DNase I, cleanup reagents | Low |
| Oligo dT | Beads or resin, buffer | High |
| dsRNA Removal | Cellulose or affinity methods | Medium |
| TFF | Membranes, buffer | Medium |
| LNP Formulation | Lipids, microfluidic devices | High |
LNP formulation and chromatography are the dominant cost drivers for mRNA manufacturing. Lipid costs can exceed $10/g of mRNA for GMP-grade lipids. Oligo dT chromatography is single-use but critical for purity. Continuous manufacturing and direct encoding of modified nucleotides are reducing costs. Use
untangle.bio to model costs at your specific scale.
Frequently Asked Questions
Why is dsRNA removal critical for mRNA vaccine quality?
dsRNA is a potent pathogen-associated molecular pattern (PAMP) that activates MDA5 and RIG-I receptors in the cytoplasm, triggering type I interferon responses. This can cause inflammation, reduce antigen expression, and induce immune tolerance rather than protection. Regulatory agencies require <0.1% dsRNA in mRNA vaccine products. Cellulose chromatography effectively removes dsRNA while preserving full-length mRNA.
What is the difference between Cap0 and Cap1 mRNA?
Cap0 (m7GpppN) is the initial co-transcriptional cap added by capping enzymes. Cap1 (m7GpppNm) has an additional 2′-O-methylation on the first ribose, which significantly reduces innate immune activation. Modern mRNA vaccines use Cap1 mRNA produced either by co-transcriptional capping with trinucleotide cap analogs (CleanCap) or by two-step enzymatic capping with 2′-O-methyltransferase.
Can mRNA purification use continuous processing?
Yes, continuous mRNA manufacturing is being adopted for scale and cost. Perfusion-style IVT with continuous oligo dT capture and in-line dsRNA removal can reduce processing time and equipment footprint. However, the need for sterility and regulatory requirements for batch release testing must be considered. Hybrid approaches using continuous downstream with batch formulation are common.
Build Your mRNA Manufacturing Process
Drag-and-drop the full mRNA production train, simulate mass balance, and estimate LNP vaccine manufacturing costs.
Open untangle.bio